Chronic respiratory insufficiency is inevitable in the course of disease progression in patients with Duchenne muscular dystrophy (DMD). Without mechanical ventilation (MV), morbidity and mortality are highly likely towards the end of the second decade of life. The present review reports evidence and clinical implications regarding DMD patients treated with MV. There is no doubt that nocturnal hypercapnia precedes daytime hypercapnia. Historical comparisons have provided evidence that non-invasive intermittent positive pressure ventilation (NIPPV) at night is effective and improves quality of life and survival by 5-10 years. By contrast, the optimal criteria and timing for initiation of NIPPV are inconsistent. A recent randomized study however demonstrated the benefits of commencing NIPPV as soon as nocturnal hypoventilation is detected (Ward S, et al., Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax 2005; 60: 1019-24). The respective role of the three hypotheses of the indirect action of nocturnal NIPPV on daytime blood gases may be complimentary; the main improvement may be due to improved ventilatory response to CO 2 . The ultimate time to offer full time ventilation with the most advantageous interface is lacking in evidence. Full time NIV is possible with a combination of a nasal mask during the night and a mouthpiece during the day, however tracheostomy may be provided when mechanical techniques of cough-assistance are useless to treat chronic cough insufficiency. Chronic Respiratory Disease 2007; 4: [167][168][169][170][171][172][173][174][175][176][177] Key words: Duchenne; hypercapnia; neuromuscular diseases; noninvasive ventilation; respiratory failure Correspondence: Michel Toussaint, ZH Inkendaal, Inkendaalstraat, 1, B-1602 Vlezenbeek, Belgium. E-mail: michel.toussaint@inkendaal.be specific studies with DMD patients, but non-specific studies in the neuromuscular (NM) population including DMD patients are used when specific studies are deficient. In addition, this review includes recommendations for further research when the matter is controversial or unexplored.
Introduction
Chronic respiratory insufficiency (CRI) is an inevitable complication in the disease progression of patients with Duchenne muscular dystrophy (DMD). Patients with DMD who are not treated with mechanical ventilation (MV) typically die between the age of 19-21.5 years old. 1, 2 The variability of respiratory progression can be assessed by regular vital capacity (VC) measurements. Pre-adolescents DMD patients with optimal respiratory muscle strength can have a VC plateau of Ն2500 mL while the weaker patients reach a VC plateau Յ1500 mL. 3 During adolescence, VC decreases at a rate of 8-12%/year; [2] [3] [4] [5] when VC Ͻ 1 L, oxygen desaturations, uncontrolled hypercapnia and pending death within 12 months are highly predictable. 2, 6 In DMD patients, hypercapnic CRI typically evolves in four stages: Stage 1, sleep disordered breathing (SDB) without hypercapnia; stage 2, SDB with hypercapnia during rapid eye movement (REM) sleep; stage 3, SDB with hypercapnia during REM and non-REM sleep and stage 4, diurnal hypercapnia. [7] [8] [9] [10] [11] At stage 4, mean survival is less than one year if no ventilation is offered. 12 At stages 2 and 3, intervention with MV corrects hypercapnia, improves survival and quality of life. 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The aim of this review is to evaluate 20 years of published literature on MV in DMD patients with chronic respiratory failure; management of MV in acute situation will not be discussed. This review includes available evidence supporting current opinion. Consensuses and expert opinion are discussed where evidence is unavailable. Priority is given to specific studies with DMD patients, but non-specific studies in the neuromuscular (NM) population including DMD patients are used when specific studies are deficient. In addition, this review includes recommendations for further research when the matter is controversial or unexplored.
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Mechanical ventilation in
The need for a protocol to detect CRI
The need for systematic detection of the risks for CRI is evident. 23 We know nocturnal hypoventilation precedes daytime hypoventilation for some years in disease progression of DMD patients ( Figure 1 ). 23 Hypoventilation during REM-sleep was first reported in 1975 in generalized NM patients 24 and in 1984 in DMD patients. 10 After 1987, breathing disorders during sleep were extensively documented. 25, 26 Interestingly, one study investigating daytime MV during wakefulness was able to reverse nocturnal hypoventilation with similar benefits as with ventilation during sleep. 27 This implies that respiratory improvement obtained with daytime ventilation was not directly mediated by an effect on sleep quality. This observation suggests that sleep deterioration may trigger and complicate nocturnal hypoventilation rather than inducing hypoventilation itself. 27 An obvious question is to determine the role of sleep quality monitoring (extensive polysomnography) in the protocol to detect hypercapnia in DMD patients.
Extensive polysomnography
Many studies have reported sleep statistics in DMD patients; alterations in sleep quality (arousals) and architecture (sleep fragmentation). 7, [28] [29] [30] [31] In adolescent DMD patients, 60% of apnoeas are initially obstructive. 11, 32 With disease progression apnoeas are essentially central 29 or pseudo-central (inspiratory effort too weak to be identified). 32 The presence of macroglossia was reported to exacerbate sleep apnoeas. 29 Unfortunately, no studies concluded the impact of sleep deterioration on the decision to initiate nocturnal non-invasive positive pressure ventilation (NIPPV) in DMD patients. 33 The major reason is that sleep apnoeas do not always lead to hypercapnia. 11, 24 As a consequence, there is no need to know that sleep is disrupted to initiate NIPPV. By contrast, there is a need to measure hypercapnia to initiate NIPPV. One must be aware that a full polysomnography is expensive and hospital admissions are considered a major organizational event for DMD patients. 34 
Nocturnal monitoring
Carbon dioxide tension (PCO 2 ) measurement during the night should be considered every year once VC declines, 35 and ultimately when daytime PCO 2 Ն 45 mmHg. 8 Nocturnal measurement of PCO 2 should always be considered in symptomatic patients in whom CRI is highly likely, 36 however clinically this does not always occur.
PCO 2 measurement: invasive or non-invasive technique?
There is no agreement regarding the technique to detect hypercapnia in NM patients. One concern is to know whether transcutaneous PCO 2 (TcCO 2 ) is sufficient compared to the arterial PCO 2 measurement (PaCO 2 ). PaCO 2 has the disadvantage to be measured in the morning during wakefulness therefore not reflecting PCO 2 during sleep. Despite slightly overestimating PaCO 2 , TcCO 2 has an excellent agreement with PaCO 2 in stable patients with NIPPV (r: 0.97, P Ͻ 0.001) 37 and in patients with critical illness. 38, 39 New technology using earlobe sensor 38 provides an excellent agreement between TcCO 2 and PaCO 2 (r: 0.98, P Ͻ 0.0001). 40 TcCO 2 has the advantage of being non-invasive, and easy to use. However, morning arterial or venous PCO 2 , pH and base excess should be carried out to ensure accurate baseline TcCO 2 . Overnight pulse oxymetry can be effective but is considered as less sensitive in the earlier stages of DMD disease. 6, 41 Detection of symptoms CRI develops insidiously and symptoms of respiratory failure may not be pronounced, especially in patients with nocturnal hypercapnia with low mobility such as in wheelchair bound DMD patients. 20, [42] [43] [44] The first symptoms are related to a poor sleep quality with or without hypercapnia, 41, 45 such as somnolence which is the most common complaint, 41 nightmares, morning headaches and poor concentration have also been reported. 19, 46, 47 Pure respiratory-related symptoms appear very late usually at the time of diurnal hypercapnia such as weariness, dyspnoea, orthopnoea, chest oppression, hand sweating, swallowing disturbance, loss of appetite and moodiness. 21, 48, 49 To date, no validated symptom score is available.
Detection of CRI by daytime measurements
Undoubtedly, lung function best assess the degree of respiratory muscle involvement in DMD patients. 3 Indispensable lung function measurements include VC, 2,6,7 the maximal inspiratory and expiratory pressures (MIP and MEP) at the mouth [49] [50] [51] and the peak expiratory flow during coughing (PCF). [51] [52] [53] Sniff nasal inspiratory pressure is reported as an accurate estimate of maximal inspiratory strength. However, it has been shown to underestimate inspiratory strength in the DMD population. 54 It is recommended that VC in sitting and supine position, MIP and MEP, and PCF measurements should be recorded twice a year in nonambulatory patients. 45, 55 In DMD patients, the age at which VC falls below 1 L is a best predictor of age of death than nocturnal oxygen saturation. 6, 9 Prediction of hypercapnia by the vital capacity 31 The disability score added to VC% provides a better indication of the need for MV than VC% alone. 45 
Prediction of hypercapnia by the breathing pattern
During weaning procedure, the use of the rapid and shallow breathing index (RSBI) 58, 59 and the tension time index (TTI) calculated by Ti/Ttot x Pi/MIP 59, 60 provides prediction of the ability for NM patients to self ventilate. However, additional investigations are needed to detect whether hypercapnia is related to those indexes in DMD patients. 61 The TTI 59, 62 and the endurance tests at constant inspiratory load 63 are promising indices to discriminate those DMD patients at risks for respiratory muscle fatigue approaching the need for full time-assisted ventilation.
Multidisciplinary team
There is a need for an integrated multidisciplinary team in the care of DMD patients. Such a team should include a key physician, particularly between childhood and adult transition to assure continuity in the detection of CRI. 64 There should be compassionate discussions with patients and family about respiratory progression and prognosis and about MV before CRI occurs; 24, 35 this should be with the most appropriate member of the multidisciplinary team.
The optimum timing for initiation of MV: four options
No ventilation
Assisted ventilation was seldom proposed to DMD patients 5 before the 1980's. The option of no ventilation is now universally judged as unethical in countries where the technology is available. However, in rare cases it may be ethical not to commence NIPPV where this is in accordance with the profound wishes of some well-informed patients.
Preventive use of NIPPV
The initial objective of preventive NIPPV is aimed at lowering the inevitable worsening of VC with disease progression in normocapnic and asymptomatic patients. 1, 3 Rideau et al. 18 showed preventive NIPPV resulted in long-term stabilization of VC in 70% of patients. In 1994 a French multicenter randomized study conducted by Raphael et al. 65 investigated the impact of preventive NIPPV on survival in a DMD population versus control without NIPPV. Survival rates were significantly lower in the NIPPV group. As a conclusion, prophylactic use of NIPPV in Duchenne patients was not recommended for DMD patients with VC ranging 20-50% predicted. 65 Pure prophylactic introduction of NIPPV was thereafter rejected. However, this study has been criticized for the following reasons: The families in both groups were aware that if the individual in the control arm deteriorated they would receive NIPPV, and the NIPPV arm, should use their ventilator more liberally. This advice may have caused the control arm to seek medical assistance earlier than the NIPPV arm and this may have prevented deaths. In this study, there were no recommendations that the ventilator could be used to assist in secretion clearance. Secondly, cardiac function was significantly worse in the NIPPV arm with only 10 having normal echo versus 20 in the control group, potentially biasing the results. Thirdly, Raphael et al. 65 did not measure nocturnal PCO 2 in patients with VC ranging 20-50% although DMD patients with VC Ͻ 40% are exposed at high risk of developing nocturnal hypercapnia. 8,46,57 Consequently, Raphael et al. 65 did not discriminate patients without nocturnal hypercapnia from those with nocturnal hypercapnia, although NIPPV should be considered as a treatment of nocturnal hypercapnia (see below). All these methodological shortcomings make interpretation of the results of this study 65 confusing.
'Early' initiation of NIPPV with nocturnal hypercapnia alone
Early initiation of NIPPV is a growing approach (Table 1) : NIPPV is here proposed in nocturnal hypercapnia alone, even when sleep-related symptoms are not present. 22 At this stage of respiratory involvement, DMD patients do not show severe O 2 desaturation at night. 42 Soudon et al. 15 proposed a very early approach by starting MV as soon as REM sleep hypercapnia was present, considering early MV as a curative treatment of early CRI. These authors however, could not validate their approach. Other groups suggested that a 'semi-early' approach was beneficial since hypercapnia was present either during 50% 21 or 100% sleep. 22, 55 Importantly, Ward et al. 22 recently investigated the initiation of NIPPV with patients with nocturnal hypercapnia alone in a randomized controlled study; they demonstrated that these patients are likely to deteriorate with the development of daytime hypercapnia within two years. Initiation of nocturnal NIPPV before the development of daytime hypercapnia was beneficial to the patient. Benefits included increased quality of life, relief of the symptoms, reduction of daytime hypercapnia and reduced risk of admission in ICU for decompensated respiratory failure. 22 Initiation of NIPPV in the presence of nocturnal hypercapnia alone can delay future daytime hypercapnia which occurs 4-5 years after NIPPV initiation. 48 
'Late' initiation of NIPPV with diurnal hypercapnia
In this approach, NIPPV is established when daytime hypercapnia occurs, meaning that patients have raised CO 2 levels day and night. Most patients are very symptomatic patients 66 with VC Ͻ 20% predicted 7 sometimes resulting in uncontrolled respiratory decompensation. 67 At this stage of disease progression, DMD patients will show severe O 2 desaturations at night, 11, 19, 42, 68, 69 with up to 30% sleeping time with SpO 2 Ͻ 90%. 8 Published consensuses do not clearly guide clinicians on the correct time for NIPPV initiation. A European consensus considers NIPPV initiation when 
Contraindications and precautions for NIPPV
Contraindications are rare and include: lack of consciousness, lack of cooperation from the patient, inability to maintain the airway, presence of severe bulbar impairment and a lack of nasal access. 56, 57, 71 Patients should be taught airway clearance techniques prior to the commencement of NIPPV. 24, 64, 72, [73] [74] [75] [76] Education of caregivers and families on airway clearance techniques during home NIPPV is an important factor in the success of NIPPV. 76, 77 Choice of the ventilator and settings
Ventilator
Intermittent positive pressure ventilators supplanted negative pressure ventilators previously used with DMD patients. 13, 78 Two types of positive pressure ventilators were used: volume ventilators and pressure support ventilators. Both systems have similar effects on alveolar hypoventilation, 79, 80 and on (partial) respiratory muscles unloading. [80] [81] [82] Recently, microprocessor-based ventilators were developed aiming at combining the advantages of pressure and volume ventilators. [83] [84] [85] This new generation of ventilators provides leaks compensation, targeted volume 86 and sensitive triggering for optimal synchronization 87 and comfort. 21, 78, 88, 89 During the daytime, volume ventilators are preferable 48, 77, 90 for the benefits of air-stacking 16, 74, 90 and for the absence of leaks compensations enabling mouthpiece ventilation on demand. 48, 90 
Settings
Effective ventilation is easier achieved with low-inspiratory positive airway pressures (IPAP) between Figure 2 ) has become a growing technique. 90 A recent Belgian cohort study reported use of 24 h nasal/mouthpiece ventilation in 42 DMD patients over a period of 9.6 years. 48 They concluded that it is a safe and effective form of ventilation for patients requiring 24/24 h NIV; the mean survival was 31 years. Some authors consider tracheostomy as more effective and more secure than non-invasive interfaces, 14, 20 although a similar risk of death with both non-invasive and invasive ventilation has been reported. 99 Tracheostomy offers the possibility for direct suctioning, 100 with an additional risk for tracheal erosion, 93 mucus hypersecretion, granulation tissue formation, 101 tracheobronchomalacia 93 and tracheal haemorrhage. 93, 101, 102 This morbidity may decrease the quality of life of the patient and caregivers. Patients are more likely to be cared for in an institution as opposed to the family home, 48 while families and caregivers are exposed to greater demands for care.
The appropriate time to offer tracheostomy for 24 h MV remains controversial and depends on individual experiences. 76 Traditionally, early tracheostomy is used more commonly in France compared to other countries 103 despite requiring more carer and financial resources than NIPPV. 100, 103 Undoubtedly, tracheostomy should be considered when non-invasive techniques for airway clearance have become ineffective to treat chronic cough insufficiency.
PCO 2 monitoring during MV
As suggested by many recent clinical studies, 9, 21, 22, 37, 40, 48, 68 TcCO 2 is considered as the first choice of technique to monitor nocturnal blood CO 2 tension in the follow-up of home MV.
Efficacy of MV
Quality of life and symptoms
DMD patients consider home MV beneficial for independent living and enhancing their overall health 104 and quality of life 9,14,21,68 while health-related quality of life further decreases without MV. 105 Nocturnal NIPPV reverses symptoms associated with poor sleep quality 22, 47, 66 and full time MV reverses symptoms associated with daytime dyspnoea. 48, 55 Quality of life may be perceived differently in function of the interface. Tracheostomized patients express fewer positive statements than those ventilated non-invasively. 104, 106 Blood gas improvement A consensus report 23 and a Meta-analysis 107 validated the short-term benefits of nocturnal MV on nocturnal (direct effect) and diurnal (indirect effect) blood gases in NM patients. Nevertheless, by contrast with other NM disorders, 17,20,105 PCO 2 normalization is often suboptimal in DMD patients as suggested by PCO 2 ranging 45-50 mmHg during NIPPV (table  1) . 8, 9, 12, 17, 20 This phenomenon is not explained and warrants further investigation in order to avoid biased additional daytime ventilation to compensate for ineffective nocturnal NIPPV.
Survival
Cohorts of DMD patients receiving MV were compared to patients refusing MV. 12, 15 Survival rates at 24 and 30 months were 100% 12 and 80%, 15 respectively,
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Chronic Respiratory Disease Figure 1) . 9, 48, 55, [108] [109] [110] To date, there is no data to support an enhanced survival rate depending on timing of NIPPV initiation. 34 
Ethical considerations
Quality of life is not estimated as lower by DMD patients after MV initiation, suggesting that MV itself does not adversely affect the perceived health status. 68 However, resistances to recommend MV are reported in underinformed medical teams believing that MV brings a new handicap in DMD patients' life. 111 Information given to patients and family is never unbiased and often influences the choice for MV institution and evolution, especially when full time MV is required. 106, 111, 112 The issue of euthanasia has never been reported in end-stage DMD patients.
Indirect effect of nocturnal MV on gas exchange during spontaneous breath
Three hypotheses were developed to explain the indirect mechanism of action of nocturnal MV in sustained normocapnia during the spontaneous breathing during wakefulness (SBW). 113
Respiratory muscle rest
This hypothesis is controversial and not convincing. 14 Undoubtedly, NIPPV has been shown to unload inspiratory muscles, 62, 84, 114 but the relation between muscle fatigue and respiratory failure is not evident. 115
Improvement of respiratory system compliance
In NM disorders, short sessions of 20 min per day of insufflations with positive pressure did not change the respiratory system compliance. 116, 117 The effects on compliance of NIPPV during the night have been reported as variable in DMD patients and require further investigation.
Resetting of the central respiratory centre sensitivity for CO 2 In NM disorders, resetting of the central respiratory centres may be the most important among the three hypotheses. 99, 118, 119 Many studies support the hypothesis 8, 19, 21, 25, 27, 98, 120, [121] [122] [123] that nocturnal NIPPV leads to an upward resetting of the central respiratory centre CO 2 sensitivity, indirectly reducing daytime hypercapnia. 27, 80, 119 Undoubtedly, future work is required to clarify the role of these three hypotheses at different stages of illness progression. 119 Sessions of daytime ventilation are deemed to offer interesting area of research. 27, 124, 125 What to do when NIPPV fails?
All non-invasive techniques should be fully explored before providing tracheostomy. Failure of NIPPV may occur, due to technical issues, patient's reluctance or due to disease progression. 126 
Technical issues
Technical problems include mask discomfort, leaking and gastro intestinal bloating. Mask discomfort 126 is easily solved by using another mask 64 or a custom made mask. 95 Leaking around the mask and/or by the mouth is associated with poor ventilation and sleep disruption, 88, 127, 128 and is often related to poor mask fitting, 126 to problems of timing of ventilation or to the use of excessive IPAP. 126 The strategy to reduce leaking include increasing RR (Ն23/min), 94 decreasing IPAP (Յ15 cm H 2 O) 129 or VT (Յ13 mL/kg), 94 or increasing the inspiratory/expiratory (I/E) ratio (from 1/1.5 to 1/1). 126 Mouth leaking 24 and asynchrony 87 may be improved by the use of microprocessor-based ventilators, which compensate for leaks. An additional mouth taping 24 via a chin strap 127, 128 or a cervical collar 126 is very useful in reducing mouth leaking. Mouthpiece with lip sealing or full face mask ventilation may be used when uncontrolled leaks are present. 16 Finally, gastro-intestinal bloating may be a severe complication of NIPPV. Again, limiting IPAP is useful. 126 can easily be reduced by an informal trial during a consultation to actually experience ventilation via a nasal mask. A trial is also useful in patients with learning difficulties, one must bear in mind severe learning difficulties is not a contra-indication to NIPPV, although the process can be challenging.
Disease progression
Tracheostomy ventilation has become less common within the disease progression management of DMD patients. 130 As previously said, DMD patients are being managed safely with a series of non-invasive techniques. 16, 48, 74 
Short-term physiological effects of MV
In non-NM patients receiving NIPPV, VT and Ti increase, while RR, p0.1 and the tension-time index all reduce during assisted ventilation. 62 During intervals of spontaneous breathing between periods of NIPPV, RR remains constant 131 or increases with increasing p0.1. 27 The impact on the short-term of MV on spontaneous breathing has not been studied in DMD patients.
Long-term physiological effects of MV
Long-term physiological outcomes of MV are conflicting in DMD patients: 75 VC have been shown to increase, 27, 102 to stabilize, 12, 97, 121 to decline at a slower rate 15, 18, 20 or to decline further similarly to that prior to MV. 8, 21 One explanation for the inconsistent reports may be related to the use of different types of ventilators and settings. Hospitalization rates have been reported as reduced 17, 132 or unchanged 20, 65 after initiation of MV and therefore we would recommend further investigation in this area.
Full time ventilation
When is full time MV required?
Extension of MV to daytime use is empirically driven. 14, 45, 76 The use of MV from 18 to 20/24 h has been reported with VC Յ 400 mL 14 to VC Ͻ 300 mL, respectively. 4, 91 Ventilator free time was documented as less than 15 min in patients with VC Ͻ 10% predicted. 20 The ATS consensus statement for DMD patients recommends daytime MV when PCO 2 Ͼ 50 mmHg and/or SpO 2 Ͻ 92% while awake. 133 Those criteria were recently reported as difficult to reach in symptomatic patients in whom diurnal PCO 2 Ͼ 45 mmHg served as decisive factor to extend NIPPV into the daytime. 48, 55 Worsening of the symptoms 48 and dyspnoea 55 during the day suggest a high cost of energy expenditure spent in maintaining normocapnia. Reversal of the symptoms may be expected with a few hours of daytime NIPPV, 48, 55 but this has not yet been demonstrated. Controlled investigations should help clinicians in deciding when and how to start daytime ventilation, 76 possibly by the use of a simple symptom score. 36, 46, 48 
Outcome of 24 h MV
There is little information on the outcome of 24 h MV. Three studies reported prolonged survival in DMD patients with a combination of daytime mouthpiece ventilation and nocturnal nasal NIPPV 16, 48, 89 with stabilization of VC over five years. 48 Undoubtedly, tracheostomy and intubations may be avoided on the condition that cough-assistance techniques are available. 74 With mouthpiece ventilation, the challenge of eating together with breathing via the mouth may lead to the loss of weight and consequently to the placement of enteral feeding. 133 
Conclusions
Undoubtedly, nocturnal ventilation is safe and effective to treatment in DMD patients with hypercapnia. However, the ideal timing of when to initiate nocturnal assisted ventilation remains debatable. The ultimate timing to offer full time ventilation with the most advantageous interface is also lacking in evidence. Future investigations are required to enable clinicians to refine the introduction and long-term follow-up of both nocturnal and full time-assisted ventilation in DMD patients.
